Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
13.60
+0.05 (0.37%)
At close: May 22, 2026, 4:00 PM EDT
13.62
+0.02 (0.14%)
After-hours: May 22, 2026, 7:00 PM EDT
Dr. Reddy's Laboratories Revenue
In the fiscal year ending March 31, 2026, Dr. Reddy's Laboratories had annual revenue of 337.00B INR with 3.52% growth. Dr. Reddy's Laboratories had revenue of 75.46B in the quarter ending March 31, 2026, a decrease of -11.51%.
Revenue (ttm)
337.00B INR
Revenue Growth
+3.52%
P/S Ratio
3.24
Revenue / Employee
12,117,579 INR
Employees
27,811
Market Cap
11.60B USD
Revenue Chart
* This company reports financials in INR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 337.00B | 11.47B | 3.52% |
| Mar 31, 2025 | 325.54B | 46.37B | 16.61% |
| Mar 31, 2024 | 279.16B | 33.29B | 13.54% |
| Mar 31, 2023 | 245.88B | 31.49B | 14.69% |
| Mar 31, 2022 | 214.39B | 24.67B | 13.00% |
| Mar 31, 2021 | 189.72B | 15.12B | 8.66% |
| Mar 31, 2020 | 174.60B | 20.75B | 13.49% |
| Mar 31, 2019 | 153.85B | 11.82B | 8.32% |
| Mar 31, 2018 | 142.03B | 1.22B | 0.87% |
| Mar 31, 2017 | 140.81B | -13.90B | -8.98% |
| Mar 31, 2016 | 154.71B | 6.52B | 4.40% |
| Mar 31, 2015 | 148.19B | 16.02B | 12.12% |
| Mar 31, 2014 | 132.17B | 15.90B | 13.68% |
| Mar 31, 2013 | 116.27B | 19.53B | 20.19% |
| Mar 31, 2012 | 96.74B | 22.04B | 29.51% |
| Mar 31, 2011 | 74.69B | 4.42B | 6.28% |
| Mar 31, 2010 | 70.28B | 836.00M | 1.20% |
| Mar 31, 2009 | 69.44B | 19.44B | 38.87% |
| Mar 31, 2008 | 50.01B | -79.27B | -61.32% |
| Mar 31, 2007 | 129.28B | 80.94B | 167.42% |
| Mar 31, 2006 | 48.34B | 9.70B | 25.10% |
| Mar 31, 2005 | 38.65B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Viatris | 14.56B |
| Elanco Animal Health | 4.89B |
| United Therapeutics | 3.17B |
| Neurocrine Biosciences | 3.10B |
| Amneal Pharmaceuticals | 3.05B |
| Hims & Hers Health | 2.37B |
| Alkermes | 1.56B |
| Lantheus Holdings | 1.55B |
RDY News
- 5 days ago - Dr Reddy’s rolls out oral semaglutide in India - The Times of India
- 8 days ago - Dr. Reddy's (RDY) Introduces Generic Semaglutide Injection in Canada - GuruFocus
- 8 days ago - Dr. Reddy’s launches generic Semaglutide injection in Canada - TheFly
- 9 days ago - Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada - Business Wire
- 9 days ago - Dr. Reddy's Laboratories launches generic Semaglutide Injection in Canada - Business Upturn
- 10 days ago - Pharma Stocks Today, May 15: Dr. Reddy’s Lab rises 1.32%, Lupin gains 1.19%, Strides Pharma falls 2.35% - Business Upturn
- 11 days ago - Dr. Reddy's Laboratories Q4 Earnings Call Highlights - MarketBeat
- 11 days ago - Dr Reddy's, Dixon Technology & more: Top stocks to watch today - The Times of India